Stability studies trends

10 Jul 2018

Dr Ramesh Jagadeesan, Sr. Director - Analytical Development at Recipharm, speaks to CPhI Online on the trends and challenges involved with conducting stability studies for firms that supply to multiple countries, and the advantages of using a contractor.

Globalisation and stricter quality rules are changing how firms test drug stability according to Dr Ramesh Jagadeesan, Sr. Director - Analytical Development at Recipharm, who says outsourcing is the most efficient way of carrying out this vital research.

Stability studies trends

After efficacy, stability is a drug’s most important characteristic. Determining how long it stays within potency specifications during transport and storage is vital to ensuring reliable supply, planning production and deciding expiry dates.

To make this determination drug companies test their products in conditions designed to match the destination market. This, however, can be a significant challenge for firms that supply multiple countries as Karan explains.

Why do stability studies need to be market-specific?

It is important that stability studies are tailored to the market for which the product is destined. For example, in the US market, only certain products must undergo a microbiological limit test. It is possible to justify skipping this test based on the amount of water present or water activity in the final drug product.

Whereas, in the case of the European market, microbiological tests are mandatory in stability conditions. Even the limits for this test are different depending on the market.

Also, because the ICH demands different stability storage conditions for different regions, tests have to be classified into different zones depending on the temperature and humidity conditions.

Furthermore, region-specific requirements and Pharmacopeia standards differ from country to country.

Also, logistics infrastructure plays an important role in transporting the samples for analysis from the storage chambers. Some countries request that the stability study is conducted at the final packaging site.

What are the most challenging markets for which to conduct stability studies?

The challenge is not the market per se, rather the difficulty is in understanding different guidelines set by different countries and how these vary.

Korea is a good example. Korean regulators do not accept the bracketing and matrixing approach, which is a method used in the US and Europe to reduce the number of tests required. Likewise, Korean regulators require that three product batches are tested to determine the expiration dates.

While there are differing requirements, are there any trends emerging in terms of what regulators ask to be covered during stability testing?

There are some emerging patterns in the number and size of batches that regulators want. Generally, they ask for a minimum of three initial batches to be placed into a long-term stability program to assure uniformity when establishing the expiration date.

Likewise there are common demands in terms of storage conditions. Depending upon the different climatic zones, most regulators ask that tests are performed on or near 30 degrees Celsius or at exaggerated conditions.

Similarly, it is common for regulators to ask for temperature cycling and freeze-thaw studies as well as an assessment of how transportation will impact product stability.

In addition, a growing number of agencies require that, in addition to being able to determine stability, testing methods allow manufacturers to estimate the quantity of degradants and the efficacy of the container closure system.

What are the emerging trends in stability studies in terms of customer demands?

Information management is a growing area where we are experiencing greater demand from customers. Many now ask to be notified via online messaging of any temperature excursions that occur during stability testing. It is also common for customers to request that a Laboratory Information Management System (LIMS) is implemented to allow for more efficient document management.

Beyond that, there is growing interest in establishing how drug ingredients and excipients interact and impact stability during early phase product development. The idea is that this information will help guide the creation of more effective, more stable formulations.

What are the advantages of outsourcing stability studies?

Given the growing complexity of the average stability study, there are numerous advantages associated with outsourcing this work to an expert partner.

Clearly there are cost advantages to working with a CDMO that has established stability chambers and is experienced at maintaining such operations.

CDMOs with experienced staff are also beneficial. Drug companies that outsource stability testing are able to work with dedicated experts who have capacity to develop tailor-made solutions to any issues that occur.

More generally, outsourcing stability analysis will provide time for in-house scientists to concentrate on research and development activities of niche products rather than on routine testing.

In addition, contract testing labs will not show any bias when it comes to approving the product. Testing will be done in a strict GMP environment.

What factors do sponsors need to consider when choosing a contractor for stability studies?

Choosing a CDMO to conduct stability studies on your behalf is a complex process. The ideal approach is to identify the necessary criteria and review each potential supplier against this.

There are basic criteria like ensuring the contract testing lab operates its facility under cGMP conditions and has instruments complying with 21 CFR guidelines. Similarly, contract testing labs should provide various ranges of temperature and humidity storage conditions. They must also continuously monitor and maintain the stability chambers to ensure they possess all the necessary security features.

However, there are other more performance-related considerations.

For example, studies should be performed with quick response times to enable the sponsor to file the drug product on time. Therefore, it is sensible to determine how responsive the contractor is to requests and whether they have a good communication strategy in place.

Likewise, transparency is vital. If an out of specification result is logged it is important that the contractor notifies the customer in a timely fashion.

Read More

Related news

Aptar Pharma to showcase an industry first

Aptar Pharma to showcase an industry first

12 Sep 2018

PureHale is a new portable drug delivery device designed for upper respiratory care.

Read more 
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

11 Sep 2018

The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

Read more 
New SGS biopharmaceutical testing capabilities in Illinois

New SGS biopharmaceutical testing capabilities in Illinois

11 Sep 2018

The new services will focus on quality control analysis and stability testing of biopharmaceuticals.

Read more 
Exciting skincare to protect against blue light emitted by phones and devices

Exciting skincare to protect against blue light emitted by phones and devices

10 Sep 2018

Novel, dual-acting product revitalizes and protects skin against blue light and environmental aggressors around the clock.

Read more 
24/7 life science manufacturing IT service launches

24/7 life science manufacturing IT service launches

7 Sep 2018

Faster GMP incident response and resolution times when manufacturing IT applications fail or are not running to their optimum capacity.

Read more 
Catalent signs commercial supply agreement for Aucta Pharmaceuticals' vigabatrin

Catalent signs commercial supply agreement for Aucta Pharmaceuticals' vigabatrin

6 Sep 2018

Novel dosage form employs Catalent’s proprietary stick pack dosage form.

Read more 
Sartorius and Repligen partner to introduce next-generation perfusion-enabled bioreactors

Sartorius and Repligen partner to introduce next-generation perfusion-enabled bioreactors

5 Sep 2018

Customers to benefit from simplified, scalable solutions for intensified cell culture.

Read more 
Boehringer Ingelheim to build new tablet manufacturing facility

Boehringer Ingelheim to build new tablet manufacturing facility

4 Sep 2018

Facility to manufacture innovative drugs for worldwide market launches and technologically advanced production.

Read more 
Plasticell wins military contract to develop regenerative medicines for the battlefield

Plasticell wins military contract to develop regenerative medicines for the battlefield

4 Sep 2018

Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

Read more 
Bio processing and manufacturing league table ranks US top and China bottom

Bio processing and manufacturing league table ranks US top and China bottom

3 Sep 2018

US, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.

Read more